{"result": "(\"entity\"<|>AMERICAN THYROID ASSOCIATION<|>ORGANIZATION<|>The American Thyroid Association is a professional organization that provides guidelines for the management of thyroid nodules and differentiated thyroid cancer.)\n##\n(\"entity\"<|>HAUGEN BR<|>PERSON<|>Haugen BR is one of the authors of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.)\n##\n(\"entity\"<|>THYROID NODULES<|>EVENT<|>Thyroid nodules are abnormal growths in the thyroid gland that can be benign or malignant and are addressed in the guidelines.)\n##\n(\"entity\"<|>DIFFERENTIATED THYROID CANCER<|>EVENT<|>Differentiated thyroid cancer is a type of cancer that arises from the thyroid gland and is covered in the management guidelines.)\n##\n(\"entity\"<|>CANCER MEDULAR DE TIROIDES<|>EVENT<|>Medullary thyroid cancer is a specific type of thyroid cancer that requires careful management as per the guidelines.)\n##\n(\"entity\"<|>MACHENS A<|>PERSON<|>Machens A is a researcher who has contributed to studies on biomarker-based risk stratification for medullary thyroid cancer.)\n##\n(\"entity\"<|>DRALLE H<|>PERSON<|>Dralle H is a researcher involved in the study of thyroid cancer management and risk stratification.)\n##\n(\"relationship\"<|>HAUGEN BR<|>AMERICAN THYROID ASSOCIATION<|>Haugen BR is an author of the guidelines published by the American Thyroid Association<|>8)\n##\n(\"relationship\"<|>THYROID NODULES<|>AMERICAN THYROID ASSOCIATION<|>The American Thyroid Association provides guidelines for the management of thyroid nodules<|>7)\n##\n(\"relationship\"<|>DIFFERENTIATED THYROID CANCER<|>AMERICAN THYROID ASSOCIATION<|>The American Thyroid Association provides guidelines for the management of differentiated thyroid cancer<|>7)\n##\n(\"relationship\"<|>CANCER MEDULAR DE TIROIDES<|>AMERICAN THYROID ASSOCIATION<|>The American Thyroid Association provides guidelines for the management of medullary thyroid cancer<|>7)\n##\n(\"relationship\"<|>MACHENS A<|>CANCER MEDULAR DE TIROIDES<|>Machens A has conducted research related to the management of medullary thyroid cancer<|>6)\n##\n(\"relationship\"<|>DRALLE H<|>CANCER MEDULAR DE TIROIDES<|>Dralle H has conducted research related to the management of medullary thyroid cancer<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: que tiene al menos tres características de riesgo intermedio de recidiva, de manera que la respuesta correcta a la pregunta es la D.\n\nReferencias:\n- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1-133.\n\n## 48. Durante el seguimiento de este paciente se detecta una elevación de anticuerpos antitiroglobulina (Ac. anti-Tg). ¿Ante qué tipo de respuesta estaríamos?\n\nA. Respuesta indeterminada.\nB. Respuesta excelente.\nC. Respuesta bioquímica incompleta.\nD. Respuesta estructural incompleta.\n\n### COMENTARIO\n\nEn la clasificación dinámica de riesgo, recogida en las guías ATA 2015, se clasifica la posible respuesta en 4 grupos:\n\n- Respuesta excelente: si no hay evidencia clínica, bioquímica o anatómica de persistencia tumoral.\n- Respuesta bioquímica incompleta: con Tg sérica elevada o Ac. anti-Tg crecientes en ausencia de enfermedad localizable.\n- Respuesta indeterminada: hallazgos anatómicos y/o bioquímicos que no pueden ser clasificados fiablemente como malignos o benignos: niveles de Tg detectables, pero a bajo nivel, o con Ac. anti-Tg estables.\n- Respuesta anatómica incompleta: persistencia o aparición de enfermedad locorregional o enfermedad metastásica con o sin elevación de Tg o Ac. anti-Tg.\n\nLos niveles de Tg para incluir en uno u otro grupo son variables dependiendo de la extensión de la cirugía y de si se ha realizado ablación con I-131.\n\nEn nuestro paciente, al presentar positivización de los Ac. anti-Tg (lo que impide valorar la tiroglobulina), entra en la categoría de respuesta indeterminada (opción A correcta).\n\nReferencias:\n- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133.\n\n## 3.8 Casos clínicos. Caso clínico 2\n\n## 49. Según la Guía ATA 2015, la cirugía indicada en este caso sería:\n\nA. Tiroidectomía total.\nB. Tiroidectomía total y vaciamiento de compartimento VI.\nC. Tiroidectomía total y vaciamiento ganglionar de compartimentos II al V derechos y compartimento VI.\nD. Tiroidectomía total y vaciamiento ganglionar lateral bilateral y central.\n---\n# TIROIDES\n\n## COMENTARIO\n\nEl paciente presenta adenopatías patológicas en cadena lateral derecha y unos niveles elevados de calcitonina sérica. Indudablemente, realizar solo tiroidectomía total o acompañarla de linfadenectomía del compartimento central, sin tocar el compartimento lateral que es donde tiene las adenopatías, no sería correcto. Por lo tanto, las dos primeras opciones son falsas.\n\nLa duda sería si además de realizar el vaciamiento del compartimento lateral afectado, que es la opción C a la pregunta, estaría indicado realizar la del compartimento lateral del lado opuesto, que es la opción D.\n\nLos niveles preoperatorios de calcitonina ayudan a predecir la extensión de la enfermedad en el momento del diagnóstico y por lo tanto a la planificación de la cirugía. En el estudio de Machens y Dralle encuentran que niveles de calcitonina superiores a 200 pg/ml, como es el caso del paciente descrito, se asocian con la presencia de metástasis ganglionares en las cadenas laterales contralaterales, siendo su frecuencia mayor cuanto más elevado sea el nivel de calcitonina. Concretamente indican que, si la calcitonina es mayor de 200 pg/ml,la frecuencia es de un 14%; si es superior a 1.000, de un 18%, y si excede los 2.000, de un 44%.\n\nBasándose en estos hallazgos, la Guía ATA 2015 para el manejo del cáncer medular de tiroides indica que, en caso de niveles preoperatorios de calcitonina mayores de 200 pg/ml \"debería considerarse\" realizar linfadenectomía del compartimento contralateral (opción D correcta).\n\nReferencias:\n- Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2655-63.\n- Wells SA, Asa SL, Dralle H, Elisei R, Evan DB, Gagel RF, N, et al.\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}